A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma

Neto, Ary Serpa; Tobias-Machado, Marcos; Esteves, M. A.; Senra, M. D.; Wroclawski, Marcelo Langer; Fonseca, Fernando L. A.; Reis, Rodolfo Borges dos; Pompeo, Antônio Carlos Lima; Giglio, Auro del

doi:10.1186/1471-2490-10-9

Cited by 37 publications

(13 citation statements)

References 44 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests that androgens play an important role in regulating vitamin D metabolism and therefore calcium metabolism. Studies have shown that antiandrogen therapy in men is associated with osteoporosis and risk of fracture (48). Consistent with a role for androgens in the control of vitamin D and calcium metabolism, Francis et al (49) found that serum 1,25(OH) 2 D levels and intestinal calcium absorption increased significantly after testosterone treatment in hypogonadal men.…”

Section: Discussionmentioning

confidence: 99%

Dietary Vitamin D and Vitamin D Receptor Level Modulate Epithelial Cell Proliferation and Apoptosis in the Prostate

Kovalenko

Zhang

et al. 2011

Cancer Prevention Research

View full text Add to dashboard Cite

Low vitamin D (VD) status may increase prostate cancer risk but experimental evidence for this relationship is modest. We tested whether low VD status or VD receptor (VDR) deletion influences prostate epithelial cell (PEC) biology using intact mice, castrated mice, or castrated mice treated with testosterone propionate (TP, 2.5 mg/kg BW). PEC proliferation (Ki-67 staining) and apoptosis (TUNEL method) were determined in the anterior prostate (AP). In study 1, wild-type (WT) and TgAPT121 mice (a model of prostate intraepithelial neoplasia) were fed diets with 25, 200 (reference diet), or 10000 IU VD/kg diet (as vitamin D3) prior to castration/repletion. Serum 25 hydroxyvitamin D levels were 26, 78, and 237 nmol/L in the three diet groups, respectively. Castration reduced proliferation and increased apoptosis in the AP while TP reversed these effects. Low VD diet increased proliferation in WT (+82%) and TgAPT121 (+24%) mice while it suppressed apoptosis in WT (−29%) and TgAPT121 (−37%) mice. This diet also increased the severity of PIN lesions in the AP of intact TgAPT121 mice. In study 2, mice with PEC-specific VDR deletion (PEC VDR KO) were examined after castration/repletion. TUNEL staining was 60% lower in castrated PEC VDR KO mice compared to castrated WT mice. In castrated mice given TP, Ki-67 staining was 2-fold higher in PEC VDR KO compared to WT mice. Our data show that low diet VDR or VDR deletion provide a prostate environment that is permissive to early procarcinogenic events that enhance prostate cancer risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Dietary Vitamin D and Vitamin D Receptor Level Modulate Epithelial Cell Proliferation and Apoptosis in the Prostate

Kovalenko

Zhang

et al. 2011

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

“…Prostate cancer typically occurs at an age when serum testosterone levels are naturally decreasing in men. The initiation of ADT results in dramatic hypogonadism, which causes decreased bone mineral density (BMD) and muscle loss . Men receiving ADT have been shown to have a 5‐ to 10‐fold increased loss of BMD at multiple skeletal sites, with maximal loss occurring within the first year after ADT initiation .…”

Section: Introductionmentioning

confidence: 99%

Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen‐deprivation therapy (ADT) for prostate cancer

et al. 2013

View full text Add to dashboard Cite

What's known on the subject? and What does the study add?• There is an increase in use and duration of androgen-deprivation therapy (ADT) in patients with prostate cancer. ADT can cause decreased bone mineral density and lean muscle loss, putting these patients at increased risk of fracture. Guidelines exist for the prevention and management of bone loss in this population; however, data suggests that most patients are not receiving proper screening, evaluation, or treatment for bone loss. Research to date suggests that patients on ADT are unaware of the risks and side-effects of ADT and that most are not engaging in important preventative behaviours, e.g. calcium and vitamin D intake.• To our knowledge, there are no studies in patients on ADT specifically assessing patients' osteoporosis (OP) knowledge, self-efficacy, and feelings of susceptibility towards OP and their relationships to engagement in recommended healthy bone behaviours. We think that these data will aid in the development of health promotion uptake strategies that are directly targeted to this patient population. Objectives• To describe in patients with prostate cancer, receiving androgen-deprivation therapy (ADT): (i) knowledge, self-efficacy (SE), and health beliefs about osteoporosis (OP); (ii) current engagement in healthy bone behaviours (HBBs).• To explore the relationships between knowledge, SE, and health beliefs, and engagement in HBBs. Patients and Methods• 175 patients receiving ADT by injection completed questionnaires assessing current HBBs, OP knowledge, SE, and health beliefs (motivation, perceived susceptibility, and seriousness).• Descriptive statistics and independent samples t-tests were used to assess relationships between knowledge, SE, health beliefs, and engagement in HBBs. Results• Only 38% of patients had undergone a dual X-ray absorptiometry scan in the past 2 years. OP knowledge was low (mean [SD, range] 9.6 [4.4,[0][1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]) and perceived SE moderate (84.7 [24.5, 0-120] • Few patients met the recommendations for vitamin D intake (42%) and exercise (31%), and 15% were at risk of over-supplementation of calcium.• Patients taking calcium supplements (P = 0.04), and meeting guidelines for vitamin D (P = 0.008) and for exercise (P = 0.002) had significantly greater knowledge than those who did not.• Patients who were engaging in less than four of five HBBs had lower knowledge (P < 0.001) and health motivation (P = 0.01) than those who were engaging in four or all five HBBs. Conclusions• Most patients who are receiving ADT are not receiving appropriate screening, lack basic information about bone health, and are not engaging in the appropriate HBBs.• These findings support the application of the Health Belief Model in this population: interventions that teach patients about the implications of bone loss, encourage proper uptake of HBBs, and promote feelings of SE could increase engagement in HBBs to prevent and manage bone loss.

show abstract

“…Oral bisphosphonates are generally poorly absorbed and have gastrointestinal side effects, leading to low patient adherence with these drugs. 14 , 15 Due to lack of adherence, intravenous bisphosphonates are preferred to oral bisphosphonates in this patient population. Oral bisphosphonate use was not captured because the Medicare database does not collect details of oral therapy.…”

Section: Methodsmentioning

confidence: 99%

Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy

Holt¹,

Khan²,

Gujja³

et al. 2014

CMAR

View full text Add to dashboard Cite

BackgroundProstate cancer subjects with prostate-specific antigen (PSA) relapse who are treated with androgen deprivation therapy (ADT) are recommended to have baseline and serial bone densitometry and receive bisphosphonates. The purpose of this community population study was to assess the utilization of bone densitometry and bisphosphonate therapy in men receiving ADT for non-metastatic prostate cancer.MethodsA cohort study of men aged 65 years or older with non-metastatic incident diagnoses of prostate cancer was obtained from the Surveillance Epidemiology End Results (SEER)-linked Medicare claims between 2004 and 2008. Claims were used to assess prescribed treatment of ADT, bone densitometry, and bisphosphonates.ResultsA total of 30,846 incident prostate cancer cases receiving ADT and aged 65 years or older had no bone metastases; 87.3% (n=26,935) on ADT did not receive either bone densitometry or bisphosphonate therapy. Three percent (n=931) of the cases on ADT received bisphosphonate therapy without ever receiving bone densitometry, 8.8% (n=2,702) of the cases on ADT received bone densitometry without receiving intravenous bisphosphonates, while nearly 1% (0.90%, n=278) of the cases on ADT received both bone densitometry and bisphosphonates. Analysis showed treatment differed by patient characteristics.ConclusionContrary to the recommendations, bone densitometry and bisphosphonate therapy are underutilized in men receiving ADT for non-metastatic prostate cancer.

show abstract

A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma

Cited by 37 publications

References 44 publications

Dietary Vitamin D and Vitamin D Receptor Level Modulate Epithelial Cell Proliferation and Apoptosis in the Prostate

Dietary Vitamin D and Vitamin D Receptor Level Modulate Epithelial Cell Proliferation and Apoptosis in the Prostate

Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen‐deprivation therapy (ADT) for prostate cancer

Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy

Contact Info

Product

Resources

About